- Ludwig N, Nourkami-Tutdibi N, Backes C, Lenhof HP, Graf N, Keller A, Meese E
Circulating serum miRNAs as potential biomarkers for nephroblastoma
Pediatr Blood Cancer. 2015 Aug;62(8):1360-7. doi: 10.1002/pbc.25481 -> Abstract PubMed - Hubertus J, Günther B, Becker K, Graf N, Furtwängler R, Ferrari R, Gruhn B, Stahl R, von Schweinitz D, Stehr M
Development of hypertension is less frequent after bilateral nephron sparing surgery for bilateral Wilms tumor in a long-term survey
J Urol. 2015 Jan;193(1):262-6. doi: 10.1016/j.juro.2014.07.116 -> Abstract PubMed - Dome JS, Graf N, Geller JI, Fernandez CV, Mullen EA, Spreafico F, Van den Heuvel-Eibrink M, Pritchard-Jones K
Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration
J Clin Oncol. 2015 Aug 24. pii: JCO.2015.62.1888 -> Abstract PubMed - Tulla M, Berthold F, Graf N, Stefan R, von Schweinitz D, Spix C, Kaatsch P
Incidence, Trends, and Survival of Children with Embryonal Tumors
Pediatrics 136:e623-e632, 2015, doi: 10.1542/peds.2015-0224 -> Abstract
- Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de Kraker J, van Tinteren H, Graf N, on behalf of the SIOP Renal Tumours Study Group
Omission of doxorubicin from the treatment of stage II?III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial
The Lancet, Published online July 9, 2015 dx.doi.org/10.1016/S0140-6736(14)62395-3 -> Download
- Williams RD, Chagtai T, Alcaide-German M, Apps J, Wegert J, Popov S, Vujanic G, van Tinteren H, van den Heuvel-Eibrink MM, Kool M, de Kraker J, Gisselsson D, Graf N, Gessler M, Pritchard-Jones K
Multiple mechanisms of MYCN dysregulation in Wilms tumour
Oncotarget. 2015 Mar 30;6(9):7232-43 -> Abstract PubMed
SIOP Renal Tumor Study Group (RTSG), van den Heuvel-Eibrink MM, Pritchard-Jones K, van Tinteren H, Graf N
Response to letter commenting on "Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)"
Eur J Cancer. 2015 May;51(8):995-6. doi: 10.1016/j.ejca.2015.03.006 -> Abstract PubMed
Lehnhardt A, Karnatz C, Ahlenstiel-Grunow T, Benz K, Benz MR, Budde K, Büscher AK, Fehr T, Feldkötter M, Graf N, Höcker B, Jungraithmayr T, Klaus G, Koehler B, Konrad M, Kranz B, Montoya CR, Müller D, Neuhaus TJ, Oh J, Pape L, Pohl M, Royer-Pokora B, Querfeld U, Schneppenheim R, Staude H, Spartà G, Timmermann K, Wilkening F, Wygoda S, Bergmann C, Kemper MJ
Clinical and molecular characterization of patients with heterozygous mutations in wilms tumor suppressor gene 1
Clin J Am Soc Nephrol. 2015 May 7;10(5):825-31. doi: 10.2215/CJN.10141014 -> Abstract PubMed
Müller S, David R, Marias K, Graf N
The Standardized Histogram Shift of T2 Magnetic Resonance Image (MRI) Signal Intensities of Nephroblastoma Does Not Predict Histopathological Diagnostic Information
Cancer Informatics 2015:Suppl. 4 1-5 doi: 10.4137/CIN.S19340 -> Download
Mavinkurve-Groothuis AM, van den Heuvel-Eibrink MM, Tytgat GA, van Tinteren H, Vujanic G, Pritchard-Jones KL, Howell L, Graf N, Bergeron C, Acha T, Catania S, Spreafico F
Treatment of relapsed Wilms tumour (WT) patients: Experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG)
Pediatr Blood Cancer. 2015 Apr;62(4):598-602. doi: 10.1002/pbc.25357 -> Abstract PubMed
Godzinski J, Graf N, Audry G
Current concepts in surgery for Wilms tumor - the risk and function-adapted strategy
Eur J Pediatr Surg. 2014 Dec;24(6):457-60. doi: 10.1055/s-0034-1396425 -> Abstract PubMed
Wegert J, Ishaque N, Vardapour R, Geörg C, Gu Z, Bieg M, Ziegler B, Bausenwein S, Nourkami N, Ludwig N, Keller A, Grimm C, Kneitz S, Williams RD, Chagtai T, Pritchard-Jones K, van Sluis P, Volckmann R, Koster J, Versteeg R, Acha T, O'Sullivan MJ, Bode PK, Niggli F, Tytgat GA, van Tinteren H, van den Heuvel-Eibrink MM, Meese E, Vokuhl C, Leuschner I, Graf N, Eils R, Pfister SM, Kool M, Gessler M
Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors
Cancer Cell, Volume 27, Issue 2, 9 February 2015, Pages 298-311, doi: 10.1016/j.ccell.2015.01.002 -> Download
van den Heuvel-Eibrink MM, van Tinteren H, Bergeron C, Coulomb-L'Hermine A, de Camargo B, Leuschner I, Sandstedt B, Acha T, Godzinski J, Oldenburger F, Gooskens SL, de Kraker J, Vujanic GM, Pritchard-Jones K, Graf N
Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)
Eur J Cancer. 2015 Jan 12. pii: S0959-8049(14)01171-X. doi: 10.1016/j.ejca.2014.12.011 -> Abstract PubMed
